Eli Lilly Price Target Raised to $1,050 by Berenberg Bank

Analysts see continued growth potential for pharmaceutical giant

Mar. 1, 2026 at 10:31am

Got story updates? Submit your updates here. ›

Berenberg Bank has increased its price target for Eli Lilly and Company (NYSE:LLY) from $950 to $1,050, maintaining a 'hold' rating on the stock. The move comes as several other analysts have also raised their price targets for Lilly, citing the company's strong financial performance and growth prospects in its pharmaceutical pipeline.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, with a diverse portfolio of drugs across various therapeutic areas. Positive analyst sentiment and increased price targets suggest Wall Street's confidence in the company's ability to continue delivering solid financial results and developing new innovative medicines.

The details

Berenberg Bank cited Lilly's robust financial performance, including strong quarterly earnings and revenue growth, as reasons for the increased price target. The bank also noted the company's promising pharmaceutical pipeline, with several new drug candidates in late-stage clinical trials. Other analysts, such as those from UBS, Leerink Partners, and Deutsche Bank, have also raised their price targets for Lilly in recent weeks, reflecting the overall positive outlook for the company.

  • Berenberg Bank published the updated price target on Thursday, February 20, 2026.

The players

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Berenberg Bank

A German private bank that provides investment banking, asset management, and private banking services. Berenberg Bank has issued a 'hold' rating and a new price target of $1,050 for Eli Lilly and Company.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The increased price target from Berenberg Bank and other analysts reflects the pharmaceutical industry's confidence in Eli Lilly's ability to continue delivering strong financial results and developing innovative new drugs. This positive sentiment suggests the company is well-positioned to maintain its leadership position in the global pharmaceutical market.